Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Outcomes of Femtosecond Laser-assisted Pterygium Surgery (FLAPS) (FLAPS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02866968
Recruitment Status : Completed
First Posted : August 15, 2016
Last Update Posted : November 21, 2017
Sponsor:
Information provided by (Responsible Party):
Jodhbir Mehta, Singapore Eye Research Institute

Brief Summary:
The study will be a pilot interventional case series aiming to treat 30 patients with Femtosecond Laser-assisted Pterygium Surgery (FLAPS). All patients included will undergo FLAPS in one eye. All procedures will be performed in SNEC by fully qualified surgeons. The doctor is informed of the procedure on the day of.

Condition or disease Intervention/treatment Phase
Pterygium Procedure: FLAPS Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Outcomes of Femtosecond Laser-assisted Pterygium Surgery (FLAPS)
Actual Study Start Date : July 6, 2016
Actual Primary Completion Date : June 2017
Actual Study Completion Date : June 2017

Arm Intervention/treatment
Experimental: Femtosecond Laser-assisted Pterygium Surgery (FLAPS)
All patients included will undergo FLAPS in one eye.
Procedure: FLAPS
Surgical procedures will involve 1) excision of pterygium tissue from cornea and conjunctiva, 2) resection of residual Tenon and coagulation to stop any bleeding 3) preparation of a 8x8 mm conjunctiva autograft in the superior bulbar conjunctiva with the femtosecond laser (12 o´clock position) and 4) fixation of the graft with fibrin glue to the resection site.




Primary Outcome Measures :
  1. Safety and Tolerability of FLAPS [ Time Frame: 12 month follow-up ]
    Number of participants with treatment-related adverse events as assessed by CTCAE v4.0


Secondary Outcome Measures :
  1. Recurrence free survival over 12 months. [ Time Frame: 12 month follow-up ]
    Number of cases with pterygium recurrence during 12 month follow-up

  2. Visual acuity [ Time Frame: Day 0, 7 and 1, 3, 6, 12 months ]
    Best-spectacle corrected visual acuity (BSCVA) to be measured with a Snellen chart at 6 meters, then converted to logarithmic minimum angle of resolution unit to allow for averaging and statistical analysis

  3. Refraction [ Time Frame: Day 0, 7 and 1, 3, 6, 12 months ]
    Non-invasive non-contact measurement with autorefractor measured in spherical and cylindrical diopters

  4. Corneal Topography [ Time Frame: (Day 0, 7 and 1, 3, 6, 12 months) ]
    Non-invasive non-contact scan with OCULUS Pentacam, measurement of cylindrical diopters



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • A pterygium will be defined as a wing-shaped growth of fibrotic connective tissue onto the cornea originating from the nasal conjunctiva.
  • Only patients older than 21 years will be included.
  • No gender criteria are applied.
  • Only individuals with the mental capacity to provide informed consent will be included.

More specifically, all the following inclusion criteria must be met:

  • Patients have primary pterygium encroaching onto the cornea by a minimum of 1 mm.
  • Patients are willing and able to sign a written Informed Consent Form prior to any study-specific procedures.
  • Patients are willing and able to return for scheduled follow-up examinations for 12 months after the surgery.

Exclusion Criteria:

  • Patients with prior history of pterygium surgery.
  • Patients with a prior history of glaucoma filtration surgery.
  • Patients with optic atrophy.
  • Patients with ocular pathology or disease that might confound the outcome or increase the risk of adverse events.
  • Patients with a prior history of vitrectomy.
  • Patients with central corneal scarring.
  • Patients with residual, recurrent, active or uncontrolled eyelid disease.
  • Patients with any conjunctival scarring other than pterygium, that could affect surgery outcome.
  • Patients with anterior segment pathology.
  • Patients with any corneal abnormality.
  • Patients with any progressive retinal disease or subjects with a history or evidence of retinal vascular occlusion and/or hypercoagulability, because of the risks associated with high pressures during suction application.
  • Patients with amblyopia or strabismus or those who are at risk for developing strabismus postoperatively as determined by corneal light reflex and cover-uncover testing.
  • Patients who are pregnant, lactating, of child-bearing potential and not practising a medically approved method of birth control, or planning to become pregnant during the course of the trial, and patients with other conditions associated with fluctuation of hormones that could lead to refractive changes.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02866968


Locations
Layout table for location information
Singapore
Singapore National Eye Centre
Singapore, Singapore, 168751
Sponsors and Collaborators
Singapore Eye Research Institute
Investigators
Layout table for investigator information
Principal Investigator: Jodhbir S Mehta, Prof Singapore Eye Research Institute

Layout table for additonal information
Responsible Party: Jodhbir Mehta, Prof, Singapore Eye Research Institute
ClinicalTrials.gov Identifier: NCT02866968     History of Changes
Other Study ID Numbers: R1361/47/2016
First Posted: August 15, 2016    Key Record Dates
Last Update Posted: November 21, 2017
Last Verified: November 2017

Additional relevant MeSH terms:
Layout table for MeSH terms
Pterygium
Conjunctival Diseases
Eye Diseases